心可舒联合乙胺碘呋酮治疗冠心病快速心房纤颤45例

目的：探讨心可舒联合乙胺碘呋酮治疗冠心病快速心房纤颤的临床疗效。方法病例选自我院2011年12月~2013年12月收治的冠心病快速心房纤颤患者共90例，分为两组，其中对照组（n=45）单纯给予乙胺碘呋酮治疗，观察组（n=45）采取心可舒联合乙胺碘呋酮治疗，观察并比较两组临床治疗效果及不良反应发生情况。结果观察组总有效率为91.11%，显著高于对照组的77.78%，两组比较差异有统计学意义（P＜0.05）；观察组不良反应发生率为6.66%，显著低于对照组的26.67%，两组比较差异有统计学意义（P＜0.05）。结论心可舒联合乙胺碘呋酮治疗冠心病快速心房纤颤疗效确切，可有效控制心室率，改善临床症状，且不良反应发生率低，安全性好，具有较好的临床应用价值。

Clinical analysis of 45 cases of combined Xinkeshu tablets and amiodarone in treatment of coronary heart disease of fast atrial fibrillation

Objective To explore the clinical effect of combined Xinkeshu tablets and amiodarone in patients with coronary heart disease of fast atrial fibrillation.Methods90 cases with coronary heart disease of fast atrial fibrillation treated in our hospital from December 2011 to December 2013 were selected,that were divided into two group, patients in control group（n=45） received amiodarone treatment, observation group（n=45） received Xinkeshu and amiodarone treatment, clinical effect and adverse events were compared before and after being treated.ResultsThe effective treatment rate of observation group was 91.11%, The date was significantly higher than the 77.78% of control group, differences were statistically significant （P〈0.05）,The adverse reactions rate of observation group was 6.66%, the date was significantly lower than 26.67% of control group, Differences were statistically significant （P〈0.05）.ConclusionThe combined treatment of Xinkeshu tablets and amiodarone could obtain better curative effect in the treatment of coronary heart disease of fast atrial fibrillation, and can effectively improve the clinical symptoms and clinical treatment outcomes, and it has a low incidence of adverse reactions and drug safety,and is worth of clinical application and promotion.